Neutra Corp. (NTRR)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | -181.24 Thousand USD | 56.53% |
| 2023 | -416.92 Thousand USD | 15.69% |
| 2022 | -494.53 Thousand USD | -10.39% |
| 2021 | -386.57 Thousand USD | -13.63% |
| 2020 | -354.92 Thousand USD | 76.93% |
| 2019 | - USD | -943.91% |
| 2018 | -163.68 Thousand USD | 55.85% |
| 2017 | -370.72 Thousand USD | -135.78% |
| 2016 | -5000.00 USD | 262.93% |
| 2015 | - USD | 34.17% |
| 2014 | -965.9 Thousand USD | -213.55% |
| 2013 | -308.05 Thousand USD | -279.3% |
| 2012 | -81.21 Thousand USD | 0.0% |
| 2011 | - USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | -43.67 Thousand USD | 25.63% |
| 2024 Q1 | -51.48 Thousand USD | 78.21% |
| 2024 Q4 | -27.36 Thousand USD | 37.36% |
| 2024 FY | - USD | 56.53% |
| 2024 Q2 | -58.73 Thousand USD | -14.08% |
| 2023 Q2 | -62.62 Thousand USD | 12.7% |
| 2023 FY | - USD | 15.69% |
| 2023 Q3 | -46.34 Thousand USD | 25.99% |
| 2023 Q1 | -71.73 Thousand USD | 49.1% |
| 2023 Q4 | -236.21 Thousand USD | -409.66% |
| 2022 Q1 | -104.49 Thousand USD | 55.68% |
| 2022 Q4 | -140.94 Thousand USD | 2.21% |
| 2022 Q2 | -104.98 Thousand USD | -0.47% |
| 2022 FY | - USD | -10.39% |
| 2022 Q3 | -144.12 Thousand USD | -37.29% |
| 2021 Q3 | -83.54 Thousand USD | -4.21% |
| 2021 Q4 | -235.76 Thousand USD | -182.21% |
| 2021 Q2 | -80.16 Thousand USD | -65.24% |
| 2021 FY | - USD | -13.63% |
| 2021 Q1 | -48.51 Thousand USD | 45.37% |
| 2020 FY | - USD | 76.93% |
| 2020 Q4 | -88.8 Thousand USD | 50.88% |
| 2020 Q1 | -66.95 Thousand USD | 13.43% |
| 2020 Q2 | -57.7 Thousand USD | 13.81% |
| 2020 Q3 | -180.78 Thousand USD | -213.3% |
| 2019 Q1 | -61.84 Thousand USD | -30.48% |
| 2019 FY | - USD | -943.91% |
| 2019 Q4 | -77.33 Thousand USD | 94.87% |
| 2019 Q3 | -1.5 Million USD | -2317.34% |
| 2019 Q2 | -62.34 Thousand USD | -0.81% |
| 2018 Q4 | -47.39 Thousand USD | -83.42% |
| 2018 Q3 | -25.84 Thousand USD | 25.18% |
| 2018 FY | - USD | 55.85% |
| 2018 Q1 | -55.9 Thousand USD | 41.22% |
| 2018 Q2 | -34.53 Thousand USD | 38.22% |
| 2017 Q1 | -114.35 Thousand USD | -108.02% |
| 2017 Q2 | -94.1 Thousand USD | 17.7% |
| 2017 Q3 | -67.16 Thousand USD | 28.63% |
| 2017 FY | - USD | -135.78% |
| 2017 Q4 | -95.1 Thousand USD | -41.61% |
| 2016 Q2 | -109.87 Thousand USD | 19.21% |
| 2016 FY | - USD | 262.93% |
| 2016 Q1 | -136.01 Thousand USD | -11.63% |
| 2016 Q4 | 1.42 Million USD | 1090.42% |
| 2016 Q3 | -143.96 Thousand USD | -31.03% |
| 2015 Q3 | -164 Thousand USD | 22.51% |
| 2015 Q2 | -211.63 Thousand USD | -1.56% |
| 2015 Q1 | -208.38 Thousand USD | 19.97% |
| 2015 FY | - USD | 34.17% |
| 2015 Q4 | -121.84 Thousand USD | 25.71% |
| 2014 Q2 | -242.68 Thousand USD | -29.54% |
| 2014 FY | - USD | -213.55% |
| 2014 Q3 | -273.51 Thousand USD | -12.7% |
| 2014 Q1 | -187.34 Thousand USD | -138.56% |
| 2014 Q4 | -260.37 Thousand USD | 4.8% |
| 2013 Q2 | -97.78 Thousand USD | -20.57% |
| 2013 Q3 | -50.64 Thousand USD | 48.21% |
| 2013 Q4 | -78.52 Thousand USD | -55.06% |
| 2013 FY | - USD | -279.3% |
| 2013 Q1 | -81.09 Thousand USD | -36.32% |
| 2012 Q2 | -17.38 Thousand USD | -2977.35% |
| 2012 FY | - USD | 0.0% |
| 2012 Q1 | -565.00 USD | 0.0% |
| 2012 Q4 | -59.49 Thousand USD | -1477.2% |
| 2012 Q3 | -3772.00 USD | 78.31% |
| 2011 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 99.745% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 96.943% |
| SQZ Biotechnologies Company | -64.14 Million USD | 99.717% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 98.957% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 100.193% |
| Mesoblast Limited | -62.38 Million USD | 99.709% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 88.2% |
| Genus plc | 73.7 Million USD | 100.246% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 97.259% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 94.89% |
| Marizyme, Inc. | -34.28 Million USD | 99.471% |
| ContraFect Corporation | -64.99 Million USD | 99.721% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 97.934% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 95.996% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 87.07% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 93.146% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | 92.2% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | 65.013% |
| Accustem Sciences Inc. | -3.74 Million USD | 95.162% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 99.624% |
| EV Biologics, Inc. | -1.26 Million USD | 85.696% |
| Q BioMed Inc. | -617.62 Thousand USD | 70.654% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 105.074% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 71.34% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | 92.066% |
| Biomind Labs Inc. | -1.03 Million USD | 82.481% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 101.835% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 97.469% |
| Skye Bioscience, Inc. | -13.54 Million USD | 98.662% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | 87.815% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -624.988% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 95.334% |
| IMV Inc. | -35.52 Million USD | 99.49% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 98.858% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 92.756% |
| GB Sciences, Inc. | -1.41 Million USD | 87.235% |
| Alpha Cognition Inc. | -9.7 Million USD | 98.133% |
| HST Global, Inc. | -5303.00 USD | -3317.82% |
| CSL Limited | 4.78 Billion USD | 100.004% |
| Halberd Corporation | -74.27 Thousand USD | -144.008% |
| Enzolytics Inc. | -2.12 Million USD | 91.459% |
| Resverlogix Corp. | -11.74 Million USD | 98.456% |
| Affymax, Inc. | -14.29 Million USD | 98.732% |
| SYBLEU INC | -141.57 Thousand USD | -28.026% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 94.083% |
| argenx SE | -216.02 Million USD | 99.916% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 99.672% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 114.893% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | 87.908% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 147.842% |
| AVAX Technologies, Inc. | -6.11 Million USD | 97.035% |
| Zenith Capital Corp. | -8.6 Million USD | 97.894% |
| Genscript Biotech Corporation | -248.71 Million USD | 99.927% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -940.394% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | 92.591% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -2.967% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 99.543% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 93.734% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | 82.678% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 2795.523% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | 89.643% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | 90.565% |
| BioStem Technologies, Inc. | -7.55 Million USD | 97.601% |
| ONE Bio Corp. | 13.61 Million USD | 101.331% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -0.088% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | 91.189% |
| Agentix Corp. | -1.37 Million USD | 86.787% |
| LadRx Corporation | 412.28 Thousand USD | 143.962% |
| Cell Source, Inc. | -4.27 Million USD | 95.758% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | 50.644% |
| Regen BioPharma, Inc. | 1.46 Million USD | 112.364% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | 80.656% |
| NovAccess Global Inc. | -1.03 Million USD | 82.485% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 102.047% |
| Itoco Inc. | -1.86 Million USD | 90.302% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | 52.256% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 83.759% |
| Kadimastem Ltd | -2.62 Million USD | 93.094% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | 24.212% |
| CytoDyn Inc. | -18.02 Million USD | 98.995% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -129.342% |
| Mobile Lads Corp. | -2.24 Million USD | 91.913% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -1382.108% |
| Qrons Inc. | -40.08 Thousand USD | -352.202% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | 62.682% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 134.364% |
| Rebus Holdings, Inc. | -951 Thousand USD | 80.941% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | 82.934% |
| International Stem Cell Corporation | 202 Thousand USD | 189.726% |
| Bioxytran, Inc. | -3.82 Million USD | 95.255% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -244.314% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | 92.638% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 99.495% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -302.771% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 93.38% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 99.101% |
| PureTech Health plc | -11.62 Million USD | 98.441% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 99.101% |
| IXICO plc | -707 Thousand USD | 74.364% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 97.642% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 99.625% |
| CSL Limited | 4.73 Billion USD | 100.004% |
| Cellectis S.A. | -92.63 Million USD | 99.804% |